E-LIB Suche - Ergebnisse für: Ohlssen, David

1

Predicting subgroup treatment effects for a new study: Moti..:

Bornkamp, Björn ; Zaoli, Silvia ; Azzarito, Michela...
Pharmaceutical Statistics. 23 (2024) 4 - p. 495-510 , 2024

2

All that Glitters Is not Gold: Type‐I Error Controlled Vari..:

Zimmermann, Manuela R. ; Baillie, Mark ; Kormaksson, Matthias..
Clinical Pharmacology & Therapeutics. 115 (2024) 4 - p. 774-785 , 2024

Link: https://doi.org/10.1002/..

3

A framework for longitudinal latent factor modelling of tre..:

Falck, Fabian ; Zhu, Xuan ; Ghalebikesabi, Sahra...
Journal of Biomedical Informatics. 154 (2024) - p. 104641 , 2024

Link: https://doi.org/10.1016/..

4

A deep learning approach to private data sharing of medical..:

Sun, Hanxi ; Plawinski, Jason ; Subramaniam, Sajanth...
PLOS ONE. 18 (2023) 7 - p. e0280316 , 2023

Link: https://doi.org/10.1371/..

5

Good Data Science Practice: Moving Toward a Code of Practic..:

Baillie, Mark ; Moloney, Conor ; Mueller, Carsten Philipp...
Statistics in Biopharmaceutical Research. , 2022

Link: https://doi.org/10.1080/..

6

Comparing algorithms for characterizing treatment effect he..:

Sun, Sophie ; Sechidis, Konstantinos ; Chen, Yao...
Biometrical Journal. 66 (2022) 1 - p. , 2022

Link: https://doi.org/10.1002/..

7

Sequential knockoffs for continuous and categorical predict..:

Kormaksson, Matthias ; Kelly, Luke J. ; Zhu, Xuan...
Statistics in Medicine. 40 (2021) 14 - p. 3313-3328 , 2021

Link: https://doi.org/10.1002/..

8

Using knockoffs for controlled predictive biomarker identif..:

Sechidis, Konstantinos ; Kormaksson, Matthias ; Ohlssen, David
Statistics in Medicine. 40 (2021) 25 - p. 5453-5473 , 2021

Link: https://doi.org/10.1002/..

9

Functional Mixed Effects Model for the Analysis of Dose-Tit..:

Chen, Ji ; Ohlssen, David ; Zhou, Yingchun
Statistics in Biopharmaceutical Research. 10 (2018) 3 - p. 176-184 , 2018

Link: https://doi.org/10.1080/..

10

Estimands and Their Role in Clinical Trials:

Akacha, Mouna ; Bretz, Frank ; Ohlssen, David..
Statistics in Biopharmaceutical Research. 9 (2017) 3 - p. 268-271 , 2017

Link: https://doi.org/10.1080/..

11

Multiple Sclerosis Care Optimization Tool (MS-COT): A Clini..:

Silva, Diego ; Meier, Daniela Piani ; Ritter, Shannon...
Neurology. 88 (2017) 16_supplement - p. , 2017

Link: https://doi.org/10.1212/..

12

On the Optimal Timing of Futility Interim Analyses:

Xi, Dong ; Gallo, Paul ; Ohlssen, David
Statistics in Biopharmaceutical Research. 9 (2017) 3 - p. 293-301 , 2017

Link: https://doi.org/10.1080/..

13

Bayesian Two-Stage Dose Finding for Cytostatic Agents Via M..:

Xu, Jiajing ; Yin, Guosheng ; Ohlssen, David.
Journal of the Royal Statistical Society Series C: Applied Statistics. 65 (2016) 3 - p. 465-482 , 2016

Link: https://doi.org/10.1111/..

14

Strategies on Using Prior Information When Assessing Advers..:

Weaver, Jerry ; Ohlssen, David ; Li, Judy X.
Statistics in Biopharmaceutical Research. 8 (2016) 1 - p. 106-115 , 2016

Link: https://doi.org/10.1080/..

15

Model averaging for treatment effect estimation in subgroup..:

Bornkamp, Björn ; Ohlssen, David ; Magnusson, Baldur P..
Pharmaceutical Statistics. 16 (2016) 2 - p. 133-142 , 2016

Link: https://doi.org/10.1002/..